<DOC>
	<DOCNO>NCT00695370</DOCNO>
	<brief_summary>Hypothesis : pegfilgrastim 300 µg/kg hematological steady state provide efficient stem cell mobilization child malignancy Design : phase 2 study . Judgment criterion : percentage child achieve least 5x10e6 CD34 cell standard apheresis ( le 2 blood volume process )</brief_summary>
	<brief_title>Evaluation Pegfilgrastim Stem Cell Mobilization Children</brief_title>
	<detailed_description>Patients : consecutively refer HSC mobilization . At least 17 day previous chemotherapy . No hematological growth factor 8 previous day . Mobilization : one sc injection 300 µg/kg pegfilgrastim ( Neulasta , Amgen ) Evaluation study : CD34 circulate cell day 2 day 7 ; AE record Judgment criterion : percentage child achieve least 5x10e6 CD34 cell standard apheresis ( le 2 blood volume process ) Analysis : sequential Bayesian study</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<criteria>0 18 year solid malignancy Lansky score &gt; 70 % 17 day since begin last chemotherapy cycle absolute neutrophil count ( ANC ) great 1×109/l administration hematopoietic growth factor previous 8 day clinical biological condition preclude mobilization collection procedure</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>June 2008</verification_date>
	<keyword>Children</keyword>
	<keyword>cancer</keyword>
	<keyword>Bone marrow transplantation</keyword>
	<keyword>Mobilization</keyword>
	<keyword>G-CSF</keyword>
	<keyword>Children solid malignancy</keyword>
</DOC>